R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director GI Forecasting

Supply Chain ManagementConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • A bachelor's degree in business, life sciences, statistics, or economics is required; an advanced degree (MBA, MS, MPH, or PhD) is preferred.
  • At least 8 years of experience in pharmaceutical, biotechnology, or consulting roles, including at least 5 years in forecasting, analytics, or demand planning.
  • Demonstrated experience building and maintaining patient-based and/or demand-based forecasting models supporting commercial and operational decision-making.
  • Strong understanding of forecasting methodologies, including patient-based modeling, scenario analysis, and data-driven forecasting approaches.
  • Proficiency in analytics and visualization tools such as Excel, Tableau, Power BI, or equivalent.
  • Experience working with secondary data sources such as IQVIA and integrating multiple data streams into forecasting models.
  • Strong analytical and problem-solving skills, with the ability to synthesize complex data into actionable insights.
  • Demonstrated ability to collaborate effectively across cross-functional teams and contribute to decision-making processes.
  • Strong organizational skills and attention to detail, with the ability to manage multiple priorities in a fast-paced environment.
  • Effective communication skills, including the ability to clearly present analyses and insights to diverse stakeholders.

Responsibilities

  • Develop, maintain, and refine short-term demand forecasts across U.S. oncology products, including SKU-, dose-, and channel-level projections to support supply chain and commercial planning.
  • Build and manage patient-based forecasting models incorporating oncology-specific dynamics such as incidence, biomarker segmentation, lines of therapy, treatment duration, and market evolution.
  • Conduct scenario, sensitivity, and risk analyses to evaluate key business drivers and inform near-term decision-making.
  • Translate complex data, assumptions, and model outputs into clear, actionable insights to support launch planning, performance tracking, and operational readiness.
  • Partner cross-functionally with Commercial, Finance, Market Access, Medical Affairs, Supply Chain, and Manufacturing to gather inputs, validate assumptions, and ensure alignment on forecast outputs.
  • Support development of production and inventory strategies by providing accurate and timely forecast updates and analyses.
  • Integrate real-world data, secondary data sources such as IQVIA, and competitive intelligence into forecasting models to enhance accuracy and responsiveness.
  • Execute forecasting activities in alignment with U.S. Forecasting strategy and methodologies established by senior leadership, ensuring consistency and rigor.
  • Support enhancements to forecasting processes, tools, and data infrastructure, including model standardization and automation initiatives.
  • Maintain clear and transparent documentation of forecasting methodologies, assumptions, and data sources.
  • Manage external vendors and data partners to ensure delivery of high-quality inputs and analyses.
  • Escalate key risks, assumptions, and forecast variances to senior leadership with clear summaries and recommendations.
  • Stay current on the company’s portfolio, competitive landscape, and evolving oncology market dynamics.
  • Travel as needed and perform other duties as assigned.

Desired Qualifications

  • Experience working with oncology data and/or oncology markets.
  • Experience in oncology forecasting, including patient flow modeling and treatment dynamics.
  • Experience supporting product launches or pre-commercial forecasting.
  • Familiarity with supply chain or manufacturing planning processes.
  • Experience working in a fast-paced, growth-stage biotechnology organization.
  • Experience managing vendors or external analytics partners.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs